Skip to content

Prophylactic use of indomethacin suppositories during the perioperative period to prevent post-pancreatectomy acute pancreatitis: a study protocol for a multicenter, blind, randomized clinical trial

Prophylactic use of indomethacin suppositories during the perioperative period to prevent post-pancreatectomy acute pancreatitis: a study protocol for a multicenter, blind, randomized clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098972
Enrollment
Unknown
Registered
2025-03-17
Start date
2025-03-17
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-pancreatectomy acute pancreatitis

Interventions

Indomethacin Group:100 mg indomethacin suppository will be administered within 5 minutes after anesthesia. On postoperative day 1 (POD1), a 50 mg indomethacin suppository will be given twice, once in
Placebo Group:Placebo suppositories will be administered three times at the same time points as the indomethacin group: within 5 minutes after anesthesia, and in the morning and afternoon of postopera

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1 Age between 18 and 75 years; 2 Scheduled to undergo pancreaticoduodenectomy; 3 Truly informed and willing to participate in this study, with written informed consent signed.

Exclusion criteria

Exclusion criteria: 1 Allergy to indomethacin suppositories, aspirin, or other NSAIDs; 2 Use of NSAIDs within the past 7 days (aspirin =300 mg is acceptable); 3 Rectal disease or inability to tolerate rectal suppositories; 4 Severe cardiopulmonary complications; 5 Renal insufficiency (serum creatinine >1.4 mg/dL); 6 Concurrent known malignant tumors or other abdominal neoplastic diseases; 7 History of upper abdominal surgery; 8 Elevated serum amylase/lipase levels above the upper normal limit within one week before surgery; 9 Preoperative CT scan indicating acute pancreatic inflammation; 10 Known chronic calcific pancreatitis; 11 Scheduled for surgical procedures other than pancreaticoduodenectomy, including total pancreatectomy, distal pancreatectomy, central pancreatectomy, or tumor enucleation; 12 Refusal or inability to cooperate with the study.

Design outcomes

Primary

MeasureTime frame
Incidence of post-pancreaticoduodenectomy acute pancreatitis (ISGPS classification);

Secondary

MeasureTime frame
The incidence of postoperative hyperamylasemia (ISGPS classification);The incidence of major complications (Clavien-Dindo >= 3);The incidence of postoperative pancreatic fistula (ISGPS classification);The incidence of post-pancreatectomy hemorrhage (ISGPS classification);The incidence of delayed gastric emptying (ISGPS classification);The incidence of postoperative infection;Relaparotomy;Mortality;Postoperative length of stay;Total hospitalization cost;Postoperative C-reactive protein (CRP) level;

Countries

China

Contacts

Public ContactQiang Xu

Peking Union Medical College Hospital

xuqiang@pumch.cn+86 138 1009 6103

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026